StockData
Fulgent Genetics, Inc. logo

Fulgent Genetics, Inc. (FLGT) company profile

FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)

Close on Nov 17, 2026Market cap $666.15MP/E –Yield –

About Fulgent Genetics

Services-Medical Laboratories, SIC 8071

Fulgent is a technology-focused healthcare company operating two primary segments: laboratory services and therapeutic development. Its laboratory business provides anatomic pathology, precision diagnostics including next-generation sequencing, specialized oncology testing, and biopharmaceutical research services, alongside a consumer telemedicine platform called Picture. In its therapeutic segment, the company develops cancer drug candidates and antibody-drug conjugates utilizing a nano-drug encapsulation platform. Fulgent serves institutional clients, including hospitals, healthcare centers, commercial laboratories, government agencies, and corporations, as well as pharmaceutical firms, contract research organizations, health insurers, and individual patients.

The company operates clinical testing facilities in California, Texas, Georgia, Massachusetts, and Arizona, as well as an international laboratory in Australia. It conducts clinical trials for its therapeutic assets across trial sites within the United States. In addition, its intellectual property portfolio covers multiple jurisdictions, including the United States, Canada, China, Japan, Australia, New Zealand, and several European nations. The text does not disclose the specific location of the company's corporate headquarters.

Summary of the business section of Fulgent Genetics's latest annual report, written by StockData.

Company profile

Company

Legal name
Fulgent Genetics, Inc.
Founded
2011
Headquarters
El Monte, CA
Address
4399 Santa Anita Ave 91731
Phone
(626) 350-0537
Employees
1,300, Dec 31, 2025
Industry
Services-Medical Laboratories
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
DELOITTE & TOUCHE LLP, Los Angeles, California

Stock & identifiers

Ticker
FLGT
Exchange
Nasdaq
IPO date
Sep 29, 2016
Shares outstanding
28M, Jul 27, 2026
Public float
$284.30M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1674930
CUSIP
359664109
ISIN
US3596641098
FIGI
BBG00DR7LTG2
Share class FIGI
BBG00DW0QQM5
LEI
549300CL6P01M68QJ404
EIN
81-2621304

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ming HsiehChief Executive Officer, Director8,783,067
Paul KimCFO and Treasurer353,795
Jian XiePresident and COO576,379
Hanlin GaoChief Scientific Officer984,472
Michael NohaileDirector24,578
Regina E. GrovesDirector28,099
Linda DongDirector38,758

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.21M$9.49M$2.64M$50$120
FY2024$6.13M$4.06M$2.24M$35$91
FY2023$5.31M$5.04M$1.69M$55$92
FY2022$5.23M$3.45M$3.83M$57$89
FY2021$5.66M$5.66M$758.24K$193$99
FY2020$248.00K$248.00K$2.51M$404$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payOtherTotalvs. prior year
Ming Hsieh
Chief Executive Officer
$1.00M$4.00M$1.21M–$6.21M+1%
Paul Kim
Chief Financial Officer
$600.00K$1.80M$325.89K$47.46K$2.77M+18%
Hanlin Gao
Chief Scientific Officer and Laboratory Director
$513.00K$1.54M$278.64K$21.61K$2.35M+19%
Jian Xie
President and Chief Operating Officer
$615.00K$1.85M$334.04K$13.62K$2.81M+18%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 29, 2016
Offer price
$9.00
Securities offered
4,200,000
Gross proceeds
$37.80M
Exchange
Nasdaq
First trading day
Sep 29, 2016
First-day close
$9.18+2.0%
Lock-up ends (est.)
Mar 28, 2017

“The initial public offering price is $9.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Our dedicated and growing team of over 1,300 employees is a source of pride.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 17, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 23, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 26, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 21, 2020Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 29, 2016IPOInitial public offering priced (424B4 prospectus)
Sep 26, 2016ListingRegistration of securities on an exchange (Form 8-A)
Jul 15, 2016Name changeName changed from Fulgent Diagnostics, Inc. to Fulgent Genetics, Inc.

See a number that looks wrong?